Differential efficacy of docetaxel according to non‑small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors

Carney DN and Hansen HH: Non-small-cell lung cancer - stalemate or progress? N Engl J Med. 343:1261–1262. 2000. View Article : Google Scholar : PubMed/NCBI

Hanna N, Shepherd FA, Fossella FV, et al: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI

Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI

Scagliotti G, Hanna N, Fossella F, et al: The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 14:253–263. 2009. View Article : Google Scholar : PubMed/NCBI

Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI

Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI

Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI

Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar

Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI

Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 18:2095–2103. 2000.

Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 18:2354–2362. 2000.

Hayashi Y, Kuriyama H, Umezu H, et al: Class III β-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med. 48:203–208. 2009.

Wang LF, Yin HT, Qian XP, et al: β-Tubulin III mRNA expression and docetaxel sensitivity in non-small cell lung cancer. Clin Invest Med. 32:E2782009.

Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer. 47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI

Jackman D, Pao W, Riely GJ, et al: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar : PubMed/NCBI

Onoshi T, Watanabe K, Furuse K, et al: Late phase II trial of RP56976 (docetaxel) in patients with non-small-cell lung cancer. Gan To Kagaku Ryoho. 22:59–65. 1995.PubMed/NCBI

Yokoyama A, Kurita Y, Watanabe K, et al: Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer: Docetaxel Cooperative Study Group for Lung Cancer. Gan To Kagaku Ryoho. 21:2609–2616. 1994.PubMed/NCBI

Maruyama R, Nishiwaki Y, Tamura T, et al: Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 26:4244–4252. 2008. View Article : Google Scholar : PubMed/NCBI

Lee KH, Han SW, Hwang PG, et al: Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. Jpn J Clin Oncol. 36:344–350. 2006. View Article : Google Scholar : PubMed/NCBI

Hotta K, Kiura K, Toyooka S, et al: Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2:632–637. 2007. View Article : Google Scholar

Wu SG, Yang CH, Yu CJ, et al: Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer. 72:333–339. 2011. View Article : Google Scholar : PubMed/NCBI

Rudin CM, Avila-Tang E, Harris CC, et al: Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res. 15:5646–5661. 2009. View Article : Google Scholar : PubMed/NCBI